A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer

Trial Profile

A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2012

At a glance

  • Drugs Danusertib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2012 Primary endpoint 'Prostate-specific-antigen-response-rate' has not been met, according to results reported in BJU International.
    • 29 Aug 2012 Results published in the BJU International.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top